BridGene Biosciences, Inc., a leader in the discovery and development of small molecule drugs for traditionally “hard-to-drug” targets, today announced the recent completion of a $28 million Series B+ financing round. The round was led by Bayland Capital, with participation from GTJA Investment Group, Proxima Ventures, and existing investors Lapam Capital and Grains Valley Venture Capital.

Proceeds from the financing will be used to advance BGC-515, a covalent TEAD inhibitor for solid tumors, through ongoing clinical development and toward Phase 2. The funding will also support the company’s second program, expected to enter the clinic in 2027, and accelerate the development of additional programs in oncology and autoimmune diseases. In addition, the financing enhances BridGene’s capacity to expand strategic collaborations and further validate the broad applicability of its proprietary IMTAC™ chemoproteomic platform across oncology, immunology, and neurology.

Read More – ATDev Raises $3M in Seed Funding

“Our recent financing provides important resources to advance our lead program, BGC-515, a covalent TEAD inhibitor, through Phase 2 clinical development,” said Ping Cao, Ph.D., CEO and co-founder of BridGene Biosciences. “This funding will also enable us to progress additional pipeline programs toward the clinic and further expand the reach of our IMTAC™ chemoproteomic platform through strategic collaborations, as we continue to translate our discoveries into transformative therapies for patients.”

“We are excited to lead this financing round for BridGene Biosciences,” said Yuexing Su, Founding Partner of Bayland Capital. “BridGene’s IMTAC™ platform represents a powerful and differentiated approach to drug discovery, enabling the company to discover small molecules against traditionally undruggable targets. With a growing pipeline led by the covalent TEAD inhibitor BGC-515 and multiple follow-on programs across oncology and autoimmune diseases, we believe BridGene is well positioned to deliver transformative therapies to patients and generate substantial value in the biopharmaceutical field.”

Read More – Temple Digital Group Raises $5M in Seed Funding